Chemistry: analytical and immunological testing – Peptide – protein or amino acid – Glycoproteins
Reexamination Certificate
2005-12-08
2008-10-07
Weber, Jon P (Department: 1657)
Chemistry: analytical and immunological testing
Peptide, protein or amino acid
Glycoproteins
C436S817000
Reexamination Certificate
active
07432107
ABSTRACT:
The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for adminitstration of a cox-2-inhibiting compound, in particular an NSAID, selective cox-2 inhibitior, or steroid. More particularly, the present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a selective cox-2 inhibitor, comprising the steps of (a) measuring, preferably in vitro, the level of a cardiac hormone, (b) diagnosing the risk of the patient by comparing the measured level to known levels associated with different grades of risk in a patient. The most preferred cardiac hormone in the context of the present invention is NT-proBNP. Furthermore, the present invention relates to a method for diagnosing the risk of a patient to suffer from a cardiovascular complication as a consequence of administration of a cox-2 inhibiting compound, comprising the steps of (a) measuring the level of a cardiac hormone, (b) diagnosing the risk of the patient by comparing the measured level to known levels associated with different grades of risk in a patient.
REFERENCES:
patent: 2003/0022235 (2003-01-01), Dahlen et al.
patent: WO 02/083913 (2002-10-01), None
patent: WO 02/089657 (2002-11-01), None
Wells et al. Additivity of Mutational Effects in Proteins; Biochemistry, vol. 29, No. 37 (1990) pp. 8509-8517.
Seffernick et al. Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different; Journal of Bacteriology, vol. 183, No. 8 (2001) pp. 2405-2410.
Minter et al. The Clycooxygenase 2-Selective Inhibitor NS398 Inhibits Proliferation of Oral Carcinoma Cell Lines by Mechanisms Dependent and Independent of Reduced Protaglandin E2 Synthesis; Clinical Cancer Research, vol. 9 (2003) pp. 1885-1897.
Bibbins-Domingo et al. B-Type Natriuretic Peptide and Ischemia in Patients With Stable Coronary Disease; Circulation, vol. 108 (2003) pp. 2987-2992.
Bazzino et al. Relative Value of N-Terminal Probrain Natriuretic Peptide, TIMI Risk Score, ACC/AHA Prognostic Classification and Other Risk Markers in Patients With Non-ST-Elevation Acute Coronary Syndromes; European Heart Journal, vol. 25 (2004) pp. 859-866.
Giannitsis, E. Rationale for Testing the Cardiovascular Risk for Patients With Cox-2 Inhibitors on the Basis of Biomarker NT-PROBNP; Clinical Laboratory, vol. 51, No. 1-2(2005) pp. 63-72.
Bombardier, Claire, et al., “Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis,” The New England Journal of Medicine, vol. 343, No. 21, Nov. 23, 2000, p. 1520-1528.
FitzGerald, Garret A. et al., “Coxibs and Cardiovascular Disease,” New England Journal of Medicine 351; 17, Oct. 21, 2004, p. 1709-1711.
Juni, Peter et al., “Risk of cardiovascular events and rofecoxib: cumulative meta-analysis,” www.thelancet.com; vol. 364, Dec. 4, 2004, p. 2021-2029.
Topol, Eric J. et al., “Failing the Public Health—Rofecoxib, Merk, and the FDA,” New England Journal of Medicine 331;17, Oct. 21, 2004, 1707-1709.
Mukherjee, Debabrata, et al., “Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors,” JAMA, Aug. 22/29, 2001-vol. 286, No. 8, p. 954-959.
Ambrose, T., “Review of the Clinical Utility of NT-proBNP in the Diagnosis, Prognosis and Therapy Monitoring of Patients with Congestive Heart Failure,” Journal of Clinical Ligand Assay 25:2, Summer 2002, 160-166.
Bazzino, O. et al., “Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostics classification and other risk markers in patients with non-ST-elevation acute coronary syndromes,” European Heart Journal (2004) 25, 859-866.
Bibbins-Domingo, K. et al., “B-Type Natriuretic Peptide and Ischemia in Patients with Stable Coronary Disease: Data From the Heart and Soul Study,” Circulation, Journal of the American Heart Association,Dec. 16, 2003, 2987-2992.
Masson, S. et al., “Comparative Measurement of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide in Ambulatory Patients with Heart Failure,” Clin. Chem. Lab Med 2002; 40(8) 761-763.
Minter, H. et al., “The Cyclooxygenase 2-selective Inhibitor NS398 Inhibits Proliferation of Oral Carcinoma Cell LInes by Mechanisms Dependent and Independent of Reduced Prostaglandin E2 Synthesis,” Clinical Cancer Research Review, vol. 9, 1885-1897, May 2003.
Mamdani, M. et al., “Cyclo-oxygenase-2 Inhibitors Versus Non-Selective Non-Steroidal Anti-Inflammatory Drugs and Congestive Heart Failure Outcomes in Elderly Patients: a Population-based Cohort Study,” The Lancet, vol. 363, May 29, 2004, 1751-1756.
Pfister, R. et al., “Use of NT-proBNP in routine testing and comparison to BNP,” The European Journal of Heart Failure 6 (2004) 289-293.
Ruskoaho, H., “Cardiac Hormones as Diagnostics Tools in Heart Failure,” Endocrine Reviews 2(3) 341-356, 2003.
Seffernick, J. et al., “Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different,” Journal of Bacteriology 183:8 Apr. 2001, 2405-2410.
Wells, J., “Perspectives in Biochemistry,” Biochemistry 29:37 (Sep. 18, 1990) 8509-8517.
Amick Mariln L.
Martin Paul C
Roche Diagnostics Operations Inc.
Roche Diagnostics Operations Inc.
Weber Jon P
LandOfFree
Cardiac hormones for assessing cardiovascular risk does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cardiac hormones for assessing cardiovascular risk, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cardiac hormones for assessing cardiovascular risk will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4003483